229 related articles for article (PubMed ID: 35468711)
1. Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review.
Kim SJ; Kim JM
Clin Mol Hepatol; 2022 Oct; 28(4):739-753. PubMed ID: 35468711
[TBL] [Abstract][Full Text] [Related]
2. Liver transplantation for hepatocellular carcinoma.
Taketomi A; Soejima Y; Yoshizumi T; Uchiyama H; Yamashita Y; Maehara Y
J Hepatobiliary Pancreat Surg; 2008; 15(2):124-30. PubMed ID: 18392704
[TBL] [Abstract][Full Text] [Related]
3. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
[TBL] [Abstract][Full Text] [Related]
4. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
[TBL] [Abstract][Full Text] [Related]
5. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.
Pompili M; Francica G; Ponziani FR; Iezzi R; Avolio AW
World J Gastroenterol; 2013 Nov; 19(43):7515-30. PubMed ID: 24282343
[TBL] [Abstract][Full Text] [Related]
6. Liver transplantation for advanced hepatocellular carcinoma.
Lee HW; Suh KS
Clin Mol Hepatol; 2016 Sep; 22(3):309-318. PubMed ID: 27729631
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.
Sharma P; Welch K; Hussain H; Pelletier SJ; Fontana RJ; Marrero J; Merion RM
Dig Dis Sci; 2012 Mar; 57(3):806-12. PubMed ID: 21953139
[TBL] [Abstract][Full Text] [Related]
8. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma.
An HJ; Jang JW; Bae SH; Choi JY; Yoon SK; Lee MA; You YK; Kim DG; Jung ES
Liver Transpl; 2012 Dec; 18(12):1406-14. PubMed ID: 22821639
[TBL] [Abstract][Full Text] [Related]
9. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions.
Chapman WC; Garcia-Aroz S; Vachharajani N; Fowler K; Saad N; Lin Y; Wellen J; Tan B; Khan AS; Doyle MB
J Am Coll Surg; 2017 Apr; 224(4):610-621. PubMed ID: 28069527
[TBL] [Abstract][Full Text] [Related]
10. Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.
Na GH; Hong TH; You YK; Kim DG
World J Gastroenterol; 2016 Jul; 22(25):5790-9. PubMed ID: 27433092
[TBL] [Abstract][Full Text] [Related]
11. Liver transplantation for hepatocellular carcinoma within the Milan criteria versus the University of California San Francisco criteria: a comparative study.
Abdelfattah MR; Elsiesy H; Al-Manea H; Broering DC
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):398-403. PubMed ID: 29280920
[TBL] [Abstract][Full Text] [Related]
12. Section 2. Small-for-size liver graft and hepatocellular carcinoma recurrence.
Chan SC
Transplantation; 2014 Apr; 97 Suppl 8():S7-S10. PubMed ID: 24849840
[TBL] [Abstract][Full Text] [Related]
13. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis.
Parikh ND; Waljee AK; Singal AG
Liver Transpl; 2015 Sep; 21(9):1142-52. PubMed ID: 25981135
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
[TBL] [Abstract][Full Text] [Related]
15. Patient Selection for Downstaging of Hepatocellular Carcinoma Prior to Liver Transplantation-Adjusting the Odds?
Seehofer D; Petrowsky H; Schneeberger S; Vibert E; Ricke J; Sapisochin G; Nault JC; Berg T
Transpl Int; 2022; 35():10333. PubMed ID: 35529597
[No Abstract] [Full Text] [Related]
16. Prediction of hepatocellular carcinoma recurrence after liver transplantation: Comparison of four explant-based prognostic models.
Costentin CE; Amaddeo G; Decaens T; Boudjema K; Bachellier P; Muscari F; Salamé E; Bernard PH; Francoz C; Dharancy S; Vanlemmens C; Radenne S; Dumortier J; Hilleret MN; Chazouillères O; Pageaux GP; Calderaro J; Laurent A; Roudot-Thoraval F; Duvoux C;
Liver Int; 2017 May; 37(5):717-726. PubMed ID: 28199760
[TBL] [Abstract][Full Text] [Related]
17. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
[TBL] [Abstract][Full Text] [Related]
18. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions.
Pavel MC; Fuster J
World J Gastroenterol; 2018 Aug; 24(32):3626-3636. PubMed ID: 30166858
[TBL] [Abstract][Full Text] [Related]
19. Donor Polymorphisms of Toll-like Receptor 4 rs1927914 Associated with the Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation.
Shi G; Wang C; Zhang P; Ji L; Xu S; Tan X; Li H
Arch Med Res; 2017 Aug; 48(6):553-560. PubMed ID: 29221801
[TBL] [Abstract][Full Text] [Related]
20. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
